Results

1–5 of 5 results for Chirag D. Jhaveri

Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Early Fluid-Free Status & Long-Term BCVA Outcomes With Anti-VEGF Treatment in nAMD: Post Hoc Analysis of Pooled Data From HAWK & HARRIER Studies
Chirag D. Jhaveri, MD, FASRS
On Demand Cases, Courses, and Papers
2020
96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019